SEC Form 4 · accession 0001203311-19-000003
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Jan 8, 2019
Accepted (ET)
Jan 10, 2019 · 8:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 8, 2019 | M | 5,448 | $12.16 | A | 738,061 | D | |
| Common StockF3,F1 | Jan 8, 2019 | S | 5,448 | $67.01 | D | 732,613 | D | |
| Common StockF1 | Jan 8, 2019 | M | 4,600 | $12.16 | A | 737,213 | D | |
| Common StockF4,F1 | Jan 8, 2019 | S | 4,600 | $66.05 | D | 732,613 | D | |
| Common StockF1 | Jan 8, 2019 | M | 7,100 | $12.16 | A | 739,713 | D | |
| Common StockF5,F1 | Jan 8, 2019 | S | 7,100 | $65.17 | D | 732,613 | D | |
| Common StockF1 | Jan 8, 2019 | M | 3,000 | $12.16 | A | 735,613 | D | |
| Common StockF6,F1 | Jan 8, 2019 | S | 3,000 | $64.21 | D | 732,613 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F7 | $12.16 | Jan 8, 2019 | M | 5,448 | D | — | Aug 25, 2019 | Common Stock | 5,448 | 155,737 | D |
| Non-Qualified Stock Option (right to buy)F7 | $12.16 | Jan 8, 2019 | M | 4,600 | D | — | Aug 25, 2019 | Common Stock | 4,600 | 151,137 | D |
| Non-Qualified Stock Option (right to buy)F7 | $12.16 | Jan 8, 2019 | M | 7,100 | D | — | Aug 25, 2019 | Common Stock | 7,100 | 144,037 | D |
| Non-Qualified Stock Option (right to buy)F7 | $12.16 | Jan 8, 2019 | M | 3,000 | D | — | Aug 25, 2019 | Common Stock | 3,000 | 141,037 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of common stock executed in multiple transactions at prices ranging from $66.63 to $67.52. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of common stock executed in multiple transactions at prices ranging from $65.63 to $66.61. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of common stock executed in multiple transactions at prices ranging from $64.62 to $65.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6Reflects sales of common stock executed in multiple transactions at prices ranging from $63.60 to $64.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F7Shares vested at a rate of 25% on 8/25/10 and monthly thereafter until all the shares were fully vested on 8/25/13.